No Data
Shanghai Henlius Biotech Extends Key Collaborations in China
"Love Cycling, Together We Ride" The 2024 Healthy Cycling Charity Event was successfully held.
Shanghai, November 23, 2024 /PR Newswire/ -- November is International Lung Cancer Awareness Month. To enhance the society's understanding and attention towards pulmonary diseases, the "Love Your Lungs Cycling, Accompanying You and Me" 2024 Healthy Cycling Charity Event, hosted by henlius and supported by the Shanghai Fosun Public Welfare Fund and fosun pharma, will be successfully held in Shanghai on November 23. The event invited more than a hundred people including medical staff, media personnel, cycling enthusiasts, and employee volunteers to participate in this green and healthy sport of cycling, integrate health science knowledge, collectively call on the public to pay attention to lung health, advocate healthy lifestyles, and actively promote the concept of loving and protecting the lungs.
Henlius Doses First Patient in Phase 3 Study of Combo Treatment for Gastric Cancer
Shanghai Henlius Advances Privatization Plans With Fosun
Shanghai Henlius Biotech Begins Phase 3 Trial for Cancer Therapy
Henlius (02696.HK): The international multicenter Phase 3 clinical study in mainland China comparing HLX22 combined with trastuzumab and XELOX chemotherapy to trastuzumab and XELOX with or without ramucirumab as first-line treatment for locally advanced o
Gelonghui November 22nd | Henlius (02696.HK) announced that recently, a Phase III international multicenter clinical trial of HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) compared HLX22 in combination with trastuzumab and XELOX chemotherapy to trastuzumab and XELOX chemotherapy alone or in combination with pembrolizumab for first-line treatment of locally advanced or metastatic gastroesophageal junction and gastric cancer has completed the first patient dosing in mainland china. This study is a double-blind, international multicenter, randomized controlled Phase III study designed to compare HLX22 in combination with trastuzumab.
No Data
No Data
